ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Cardiovascular Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1660210
This article is part of the Research TopicNovel Strategies for the Clinical Management of Cardiovascular-Kidney-Metabolic SyndromeView all 14 articles
Novel adiposity indices and their associations with all-cause and cardiovascular mortality in individuals with cardiovascular–kidney– metabolic syndrome stages 0–3: findings from a nationwide prospective cohort study
Provisionally accepted- People's Hospital of Xinjiang Uygur Autonomous Region, 乌鲁木齐市, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background Excess visceral fat drives CKM syndrome. This study assessed how newer obesity measures relate to death risk in early CKM (stages 0-3). Methods This study included 26,899 participants with CKM stages 0-3 from the NHANES conducted between 2001 and 2018. Participants were grouped according to their baseline measurements of the adiposity indices (WWI, ABSI, WHtR, C-index, BRI, and BMI), which served as the exposure variables. Cox models, RCS curves, and two-stage Cox analyses were used to assess how novel obesity indices relate to mortality in this population. Subgroup analyses and sensitivity analyses evaluated risk differences across demographic groups and the robustness of the results. AUC, continuous NRI and IDI were used to compare the predictive performance of the novel indices and BMI for mortality. Results The final analysis included a total of 26,899 participants. At the baseline, the gender distribution was 51.08% male, with an average age of 45.39 years.Compared with the lowest quartile group, the mortality rate was higher in the higher levels of the new obesity index groups.Novel indices significantly increased the risk of mortality. WWI showed the strongest link to all-cause death (HR:1.41,95%CI:1.31 - 1.51)and cardiovascular death (HR 1.66,95%CI:1.39 - 1.99). ABSI, WWI, WHtR, and C-index had linear positive relationships with mortality. In contrast, BMI, BRI, and WHtR showed U-shaped associations with all-cause death (higher risk at both low and high values). The increased death risk linked to the new indices was greater in people aged 20-59 than in those ≥60. The incorporation of novel obesity biomarkers into the fully adjusted model significantly improved the predictive performance for adverse outcomes, as demonstrated by WWI, ABSI, and C-index. The continuous NRI values for these indices were 0.1831 (95% CI: 0.1289–0.1992), 0.2191 (0.1644–0.2877), and 0.1805 (0.1173–0.2398), with corresponding IDI values of 0.0356 (0.0193– 0.0569), 0.0572 (0.0365–0.0839), and 0.0245 (0.0118–0.0432), respectively.Conclusion Novel obesity index is closely associated with mortality risk in the early CKM population. Novel indices offer superior obesity assessment and mortality prediction in early CKM compared to BMI.
Keywords: Cardiovascular–kidney–metabolic syndrome, Obesity, novel adiposity, Body Mass Index, All-cause mortality, Cardiovascular mortality
Received: 05 Jul 2025; Accepted: 19 Sep 2025.
Copyright: © 2025 zhou, Xing, Wang, Wang, Saiyaremu, Diliyaer, Wang and Jie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zhao Wang, xjzzqwz@163.com
Li Jie, lijie090715@126.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.